Nevertheless, vulvar carcinomas can be highly heterogeneous [29, 30], and cytoplasmic immunostaining for ROCK1 protein was heterogeneous in all tumour extensions in our cases, reflecting a disadvantage of ROCK-targeting therapies in this tumour type. This evidence concerns the gene ROCK1 and vulvar carcinoma.